Literature DB >> 24820386

Number of mediastinal lymph nodes in non-small cell lung cancer: a Gaussian curve, not a prognostic factor.

Marc Riquet1, Antoine Legras2, Pierre Mordant2, Caroline Rivera2, Alex Arame2, Laure Gibault3, Christophe Foucault2, Antoine Dujon4, Françoise Le Pimpec Barthes2.   

Abstract

BACKGROUND: It has been proposed that examining a greater number of lymph nodes (LNs) in patients with non-small-cell lung cancer (NSCLC) treated by surgical resection may increase the likelihood of proper staging and affect outcome. Our purpose was to evaluate the interindividual variability and prognostic relevance of the number of LNs harvested during complete pulmonary and mediastinal lymphadenectomy performed for NSCLC.
METHODS: We prospectively collected and retrospectively reviewed the data from 1,095 patients who underwent lung cancer resection in association with systematic lymphadenectomy and pulmonary and mediastinal LN counts from 2004 to 2009. We analyzed the interindividual variability and prognostic impact of the number of LNs on overall survival (OS).
RESULTS: The mean number of harvested pulmonary and mediastinal LNs was 17.4±7.3 (range, 1-65) and was higher in male patients, right lung surgical procedures, lobectomy and pneumonectomy, N2 disease, and pIII stage. The mean number of harvested mediastinal LNs was 10.7±5.6 and was normally distributed (range, 0-49; median, 10). The 5-year survival rate was 53.8%. Overall survival was influenced by the number of involved stations (single-station versus multi-station disease, 5-year survival rates 31.5% versus 16.9%, respectively; p=0.041) but not by the number of harvested LNs, the number of harvested mediastinal LNs, or the number of positive mediastinal LNs.
CONCLUSIONS: After lung cancer resection and complete lymphadenectomy, the number of LNs is subject to normally distributed interindividual variability, with no significant impact on OS. Recommending an optimal number of nodes is therefore arbitrary. Instead, our recommendation is to perform a complete systematic pulmonary and mediastinal lymphadenectomy following established anatomical boundaries.
Copyright © 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24820386     DOI: 10.1016/j.athoracsur.2014.03.023

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  26 in total

1.  Selection for adjuvant chemotherapy in completely resected stage I non-small cell lung cancer: external validation of a Chinese prognostic risk model.

Authors:  Ulas Kumbasar; Hilgardt Raubenheimer; May Al Sahaf; Nizar Asadi; Maria Elena Cufari; Chiara Proli; Periklis Perikleous; Zakiyah Niwaz; Emma Beddow; Vladimir Anikin; Niall McGonigle; Simon Jordan; George Ladas; Michael Dusmet; Eric Lim
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

2.  The impact of positive nodal chain ratio on individualized multimodality therapy in non-small-cell lung cancer.

Authors:  Qinchen Cao; Baozhong Zhang; Lujun Zhao; Changli Wang; Liqun Gong; Jun Wang; Qingsong Pang; Kai Li; Weishuai Liu; Xue Li; Peng Wang; Ping Wang
Journal:  Tumour Biol       Date:  2015-01-27

3.  One, two, three or four ports… does it matter? Priorities in lung cancer surgery.

Authors:  Herbert Decaluwé
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

4.  Can mathematics replace anatomy to establish recommendations in lung cancer surgery?

Authors:  Marc Riquet; Ciprian Pricopi; Antoine Legras; Alex Arame; Alain Badia; Françoise Le Pimpec Barthes
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

5.  Impact of lymph node management on resectable non-small cell lung cancer patients.

Authors:  Apichat Tantraworasin; Somcharoen Saeteng; Sophon Siwachat; Tawatchai Jiarawasupornchai; Nirush Lertprasertsuke; Sarawut Kongkarnka; Chidchanok Ruengorn; Jayanton Patumanond; Emanuela Taioli; Raja M Flores
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

6.  The impact of tumor size on the association of the extent of lymph node resection and survival in clinical stage I non-small cell lung cancer.

Authors:  Brian C Gulack; Chi-Fu Jeffrey Yang; Paul J Speicher; James M Meza; Lin Gu; Xiaofei Wang; Thomas A D'Amico; Matthew G Hartwig; Mark F Berry
Journal:  Lung Cancer       Date:  2015-10-14       Impact factor: 5.705

Review 7.  Lymph node dissection after pulmonary resection for lung cancer: a mini review.

Authors:  Stylianos Korasidis; Cecilia Menna; Claudio Andreetti; Giulio Maurizi; Antonio D'Andrilli; Anna Maria Ciccone; Francesco Cassiano; Erino Angelo Rendina; Mohsen Ibrahim
Journal:  Ann Transl Med       Date:  2016-10

8.  Nodal management and upstaging of disease: initial results from the Italian VATS Lobectomy Registry.

Authors:  Alessandro Bertani; Alessandro Gonfiotti; Mario Nosotti; Paolo Albino Ferrari; Lavinia De Monte; Emanuele Russo; Gioacchino Di Paola; Piero Solli; Andrea Droghetti; Luca Bertolaccini; Roberto Crisci
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

9.  Pathologic N1 disease in lung cancer: the segmental and subsegmental lymph nodes.

Authors:  Marc Riquet; Ciprian Pricopi; Giuseppe Mangiameli; Alex Arame; Alain Badia; Françoise Le Pimpec Barthes
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 10.  [The technique of thoracic lymph node dissection].

Authors:  S Oguzhan; M Mese; M Schirren; M Baladov; J Schirren
Journal:  Chirurg       Date:  2019-12       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.